Bunnage Mark E.
EVP, Chief Scientific Officer
Bunnage Mark E. has filed 5 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: May 19, 2026.
On the most recent filing, Bunnage Mark E. is listed as EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA. Inside the rolling window, Bunnage Mark E. reported no open-market purchases and 5 open-market sales totaling $3.0M in VRTX. The largest disclosed transaction in the window is a sale of 2,437 VRTX shares on Feb 17, 2026, worth $1.2M.
Companies traded
Other insiders at VRTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.0M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Bunnage Mark E. made?
Bunnage Mark E. has filed 5 SEC Form 4 filings (10 transaction rows) across 1 company since 2026.
Which companies does Bunnage Mark E. trade?
Bunnage Mark E. has filed SEC Form 4 disclosures for 1 company, including VRTX.
When was Bunnage Mark E.'s most recent SEC Form 4 filing?
Bunnage Mark E.'s most recent SEC Form 4 filing on Tracefour is dated May 19, 2026.
What is Bunnage Mark E.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Bunnage Mark E. is listed as EVP, Chief Scientific Officer.
What is Bunnage Mark E.'s total buy and sell value in the current window?
Inside the rolling retention window, Bunnage Mark E. bought $0 and sold $3.0M based on SEC Form 4 filings.
What was Bunnage Mark E.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,437 VRTX shares on 2026-02-17, worth $1.2M, per SEC Form 4 filings.